Status:
WITHDRAWN
Vitrectomy Retinal Oxygenation
Lead Sponsor:
Stefan Sacu
Conditions:
Diabetic Macular Edema
Eligibility:
All Genders
18+ years
Brief Summary
Vitrectomy is the common treatment for patients with macular edema secondary to epiretinal membrane. Recently, in eyes with diabetic macular edema or persistent macular edema following retinal vein oc...
Eligibility Criteria
Inclusion
- male or female, at least 18 years of age.
- ophthalmoscopic evidence of epiretinal membrane scheduled for vitrectomy and membrane peeling.
- persistent diabetic macular edema
- written informed consent
- female patients of childbearing potential must have a negative urine pregnancy test.
Exclusion
- uncontrolled systemic disease
- symptoms of a clinically relevant illness in the 3 weeks before the first study day
- any ocular condition that in the opinion of the investigator would be a contraindication for the surgical procedure
- history of glaucoma, aphakie or presence of anterior chamber intraocular lens, choroidal neovascularisation, significant cataract, any ocular infection, - history of pars plana vitrectomy.
- contraindication to pupil dilation.
- need for silicon oil or gas after the surgery
- advanced diabetic retinopathy with vitreoretinal tear and/or bleeding
Key Trial Info
Start Date :
October 1 2011
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
March 1 2015
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01510691
Start Date
October 1 2011
End Date
March 1 2015
Last Update
June 29 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Opthalmology/Clinical Pharmacology
Vienna, Austria, 1090